Videos

Treatment Regimen for Patients With ALK+ Non-Small Cell Lung Cancer

A 50-Year-Old Woman With ALK-Rearranged NSCLC

Robert "Bo" Gamble, director of strategic practice initiatives at Community Oncology Alliance, shares his perspective on the 340B Drug Discount Program and the implications of the program for the oncology community. He also provides his thoughts on possible solutions for imbalances created by the program.

Manish A. Shah, MD, director of Gastrointestinal Oncology at Weill Cornell Medicine, discusses the need for targeted therapies beyond the second-line setting in esophageal cancer. While this is a deadly disease with most metastatic patients dying within a year, a recent clinical trial with pembrolizumab addresses an unmet need in the population, Shah says.

H. Jack West, MD, thoracic oncologist at the Swedish Cancer Institute of Swedish Medical Center, discusses the data with atezolizumab (Tecentriq) and pembrolizumab (Keytruda) in non-small cell lung cancer (NSCLC). West says that the choice of treatment is likely best left to the judgement of the physician and patient. 

Daniela A. Bota, MD, medical director of Neuro-Oncology at University of California Irvine, discusses the findings from a dose-escalation trial of marizomib.

Considerations for Treating Locally Advanced NSCLC

Consolidation Therapy for Locally Advanced NSCLC

Charles G. Drake, MD, PhD, director of Genitourinary Oncology at New York Presbyterian/Columbia University Medical Center, discusses his thoughts on whether sunitinib would be more successful as a treatment for patients with renal cell carcinoma if used in the neoadjuvant setting.